Organogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annually (NASDAQ:ORGO)
· seekingalpha.com
Organogenesis (ORGO) Q2 2026 earnings call recap: CMS-driven revenue drop, reduced 2026 guidance, reimbursement risks, Amnuvx FDA timeline—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...